GlassScriptPhysician profile
Hakop Mkhsyan
NPI 1518011006
$8,976.18
in general payments reported to CMS, 2019-2025
35 companies · $1,615 in 2025
The $1,615 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $886 · 2020: $728 · 2021: $2,443 · 2022: $512 · 2023: $1,195 · 2024: $1,596 · 2025: $1,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,405.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,252.51 | 2019-2025 | Evenity, Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $1,200.00 | 2021 | |
| Abbvie INC. | $841.91 | 2019-2025 | |
| Shield Therapeutics INC | $495.74 | 2023-2025 | Accrufer |
| Janssen Pharmaceuticals, INC | $456.61 | 2019-2021 | |
| Ardelyx, INC. | $367.53 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $319.78 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $229.19 | 2019-2025 | Breztri |
| Lilly USA, LLC | $220.64 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $214.09 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Ironwood Pharmaceuticals, INC | $210.72 | 2019-2023 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.59 | 2021-2025 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $194.48 | 2021-2023 | |
| Astellas Pharma US INC | $193.44 | 2020-2023 | Veozah, Myrbetriq |
| Almatica Pharma LLC | $175.95 | 2021-2025 | Loreev Xr |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $171.88 | 2023-2024 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $160.89 | 2024 | Rexulti |
| Allergan, INC. | $138.33 | 2019-2020 | |
| Amarin Pharma, INC. | $119.36 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.52 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $93.20 | 2021-2022 | |
| Lundbeck LLC | $88.68 | 2024 | Rexulti |
| Aimmune Therapeutics, INC. | $70.00 | 2024 | |
| Dexcom, INC. | $61.66 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $59.11 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $55.99 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.52 | 2021 | |
| Eisai INC. | $41.94 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $32.85 | 2023 | Evkeeza |
| Kowa Pharmaceuticals America, INC. | $27.44 | 2024-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $25.00 | 2021 | |
| Horizon Therapeutics Plc | $22.85 | 2021 | |
| Vivus LLC | $22.76 | 2023 | Pancreaze |
| Eyevance Pharmaceuticals LLC | $22.01 | 2021 | |
| Hikma Pharmaceuticals USA | $22.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hakop Mkhsyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.